
Niemann-Pick, Gaucher nerves, childhood BMI: four stories
4 stories this week: a rare childhood storage disease, neurological symptoms of Gaucher disease, breast cancer with a receptor mutation, and excess weight in children under 12. Each note says who was studied and where the result stops.
FDA approved a drug shown to lengthen survival in infantile-onset Niemann-Pick C

On 17 November 2026 the US Food and Drug Administration approved Lembaz (adrabetadex) injection to reduce the risk of death in adults and children who weigh at least 7 kg and whose neurological symptoms of Niemann-Pick disease type C began before age 6. The agency calls it the first approved treatment shown to help people with this severe form live longer. Two therapies were already approved for the disease; the announcement says neither has been shown to reduce the risk of death.
The survival figure is not from a randomised comparison of the approved use. The FDA examined 36 patients treated with Lembaz across three clinical studies and an expanded-access program, all with neurological manifestations before age 6, against a matched external control group. Treated patients had a 55% reduction in the risk of death. Median survival was 8.5 years in the treated group and 4.9 years in the control group. The announcement says that benefit was seen whether or not patients were also taking miglustat, which it describes as used off-label in this disease.
The product carries a boxed warning for hearing impairment, including permanent hearing loss. The most common side effects named are problems with hearing, balance and coordination, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea and cough. A trained clinician gives the drug as an injection into the spinal canal. The FDA estimates that Niemann-Pick C affects about 1 in 150,000 people. Approval went to Mandos, LLC, a subsidiary of Beren Therapeutics, and the drug received breakthrough-therapy designation.
FDA approved the first drug for neurological symptoms of type 3 Gaucher disease

On 18 November 2026 the FDA approved Infilbray (venglustat) tablets for the neurological symptoms of type 3 Gaucher disease in adults and children who weigh at least 15 kg. The agency calls it the first such treatment. It is described as a glucosylceramide synthase inhibitor that crosses the blood-brain barrier. Unlike type 1 Gaucher disease, type 3 also affects the brain and can impair balance, coordination, speech, memory and thinking.
Support came from a randomised, double-blind, multicentre study in 43 patients aged 12 years and older who had already received enzyme replacement and whose disease outside the nervous system was stable. They were assigned to oral Infilbray or to intravenous enzyme replacement for 52 weeks. At week 52, the FDA says the Infilbray group improved on a combined measure of ataxia and cognitive function compared with the enzyme-replacement group. The announcement does not give the size of that difference. The public registry record that matches this description is NCT05222906, a phase 3 study of venglustat in type 3 Gaucher disease with 43 participants.
The most frequently reported side effects are gastrointestinal symptoms and effects on mood. Serious psychiatric risks, including suicidal ideation and behaviour, have been reported. Animal studies identified possible clouding of vision in younger patients and adverse effects on fetal development if the drug is taken during pregnancy. The approval, with orphan-drug designation and priority review, went to Genzyme Corporation, a Sanofi company.
FDA approved giredestrant with everolimus where an ESR1 mutation is present

On 16 November 2026 the FDA approved giredestrant (Wilserdly, Genentech), an oral estrogen-receptor antagonist, in combination with everolimus for adults with estrogen-receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, detected by an FDA-authorised test, after recurrence during or after adjuvant endocrine therapy or progression on at least one endocrine regimen for metastatic disease. The agency also authorised the FoundationOne Liquid CDx assay as a companion test for this use.
Efficacy was assessed in evERA Breast Cancer, NCT05306340, a randomised open-label multicentre trial in 373 adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer, including 207 whose tumours carried ESR1 mutations. Patients were assigned 1:1 to giredestrant (183 people) or to a physician's choice of exemestane, fulvestrant or tamoxifen (190 people). Both groups also received everolimus. In the ESR1-mutated population, investigator-assessed progression-free survival had a hazard ratio of 0.38 (95% CI 0.27 to 0.54; p<0.0001). Median progression-free survival was 10 months (8.1 to 12.9) with giredestrant plus everolimus and 5.5 months (3.8 to 5.6) with the physician's choice plus everolimus. The objective response rate was 27% (18 to 37) and 14% (8 to 22). Overall survival data were immature at that analysis.
Adverse reactions in at least 20% of patients receiving giredestrant plus everolimus were stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis and nausea. The prescribing information warns of bradycardia and embryo-fetal toxicity. The review ran under Project Orbis with Health Canada and Israel's Ministry of Health; the FDA notes that those applications may still be in submission or under review. The US decision came four weeks before the FDA goal date. A longer time without progression on imaging is not the same as a longer life, and this approval does not show the second.
In children under 12, semaglutide lowered BMI more than placebo at 68 weeks

On 16 November 2026 the New England Journal of Medicine published STEP Young, a phase 3 double-blind randomised trial of once-weekly subcutaneous semaglutide in children aged 6 to under 12 years with obesity. The paper says the same medicine is already approved for obesity in adolescents and adults, and that data in younger children had been lacking. Novo Nordisk funded the trial. Several authors are employees of Novo Nordisk.
Investigators randomised 167 children in a 2:1 ratio, 112 to semaglutide and 55 to placebo, for 104 weeks, followed by a 7-week period off the study drug. Both groups received lifestyle counselling. The primary end point was the percent change in body-mass index at week 68: minus 13.5% with semaglutide and plus 2.7% with placebo, an estimated difference of minus 16.2 percentage points (95% CI minus 19.4 to minus 12.9; P<0.001). At week 104 the changes were minus 9.4% and plus 8.4%, a difference of minus 17.8 percentage points (minus 22.2 to minus 13.3).
At week 68, a lower BMI category was recorded in 79% of the semaglutide group and 23% of the placebo group (odds ratio 7.8; 95% CI 3.5 to 17.6; P<0.001). Body-mass index was below the obesity threshold, the 95th percentile for age and sex, in 38% and 2%. Adverse events occurred in 96% of children on semaglutide and 93% on placebo. Gastrointestinal events were the most common, were more frequent with semaglutide, and led to discontinuation in one child in the semaglutide group. The published conclusion is about the 68-week change in body-mass index. It is a trial result, not an approval for children under 12.
This article reports published trials and regulator decisions. It does not replace a consultation with a doctor, and it is not a recommendation to start, stop or change treatment.
Sources
FDA approves Lembaz (adrabetadex) for infantile-onset Niemann-Pick disease type C. FDA news release. 17 November 2026. fda.gov.
FDA approves Infilbray (venglustat) for neurological symptoms of type 3 Gaucher disease. FDA news release. 18 November 2026. fda.gov. NCT05222906.
FDA approves giredestrant with everolimus for ESR1-mutated ER-positive, HER2-negative advanced breast cancer. FDA. 16 November 2026. fda.gov. NCT05306340.
Jastreboff AM, Harder-Lauridsen NM, Van Name M, et al. Semaglutide for the treatment of obesity in children 6 to under 12 years of age. N Engl J Med. 16 November 2026. PMID 43037562, doi:10.1056/NEJMoa2604058, NCT05726227.
Articles in this section are educational and are not medical advice, a diagnosis, or a prescription. Consult a qualified professional before acting on anything you read here.
Read next
ResearchBiomarkersThe artery-age score was age and pressure in disguise
A person past sixty who is handed a second age can see which kind of number still sorts deaths, and which kind only repeats the page it was built from. Nothing here is a reason to chase a lower score.
ResearchMedicine and treatmentA Duchenne cell therapy was refused over unreliable data
For families following Duchenne research, a refusal can say more than a promise. Here is how to read one: what the regulator set aside, and what that decision leaves open.
ResearchMetabolismOne gut enzyme sharpened the insulin response of old male mice
Cell Metabolism reported on 16 November that raising one bacterial enzyme in aged male mice improved an insulin test about 20 weeks later. A similar bile-acid pattern shows up in centenarians, and the paper does not measure lifespan.